Please use this identifier to cite or link to this item:
http://repo.knmu.edu.ua/handle/123456789/18814| Title: | Metabolic drugs in anti-ischemic therapy |
| Authors: | Zakharenkova, A. Візір, Марина Олександрівна Vizir, Maryna Визир, Марина Александровна |
| Keywords: | anti-ischemic therapy coronary heart disease Trimetazidine thiotriazoline |
| Issue Date: | Nov-2017 |
| Publisher: | Skleněný Můstek, Karlovy Vary, Czech Republic |
| Citation: | Zakharenkova A. Metabolic drugs in anti-ischemic therapy / A. Zakharenkova // Science and Life : Proceedings of articles the international scientific conference, Skleněný Můstek, Karlovy Vary, Czech Republic, 16–17 November 2017. – Karlovy Vary, 2017. – P. 59–64. |
| Abstract: | The first drugs for anti-ischemic therapy were vitamins of group B, but their effectiveness was refuted in clinical trials. The next drug was trimetazidine, since it has a high cytoprotective effect. This drug is especially effective in patients with stable angina. But thiotriazoline is a new anti-ischemic drug that includes anti-ischemic, metabolic and antioxidant activity with minimal side effects. Summing up, given the good tolerability, efficacy and safety, thiotriazoline can be recommended as a remedy of metabolic therapy for the treatment of IHD in the elderly. |
| URI: | https://repo.knmu.edu.ua/handle/123456789/18814 |
| Appears in Collections: | Наукові роботи молодих вчених. Кафедра внутрішньої медицини № 1 |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Статья Захаренкова.docx | 25,26 kB | Microsoft Word XML | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.